New biomarkers gaining importance in heart failure management include mid-regional pro adrenomedullin (MR-proADM) and copeptin (stable C-terminal pro-peptide fragment of arginine vasopressin), indicating neurohormonal activation, ST2, and Galectin-3, indicating myocardial remodeling. The gene discussed is LGALS3; the disease is heart failure.